Literature DB >> 15123350

Experimental cholestatic liver disease through bile-duct ligation in rats results in skeletal fragility and impaired osteoblastogenesis.

Miron Weinreb1, Rivka Dresner Pollak, Zvi Ackerman.   

Abstract

BACKGROUND/AIMS: Patients with cholestatic liver disease have 'low-turnover' osteoporosis. Since we reported that bile-duct ligated (BDL) rats develop bone disease with low bone formation and mass, we examined whether their reduced bone mass results in skeletal fragility, and whether the reduction in osteoprogenitor cells could explain the depressed bone formation.
METHODS: Four-week-old rats were pair-fed and subjected to BDL or sham surgery. After 4 weeks, ex vivo bone marrow stromal cell cultures were used to estimate the number of osteoprogenitors and tibial strength was measured by mechanical testing. The serum levels of albumin, bilirubin, alanine amino-transferase (ALT), alkaline phosphatase (ALP) and nitrite were measured.
RESULTS: BDL rats had elevated levels of bilirubin, ALT, ALP and nitrite. Tibiae of BDL rats were weaker than those of sham rats, exhibiting lower maximal force (-34%) and stiffness (-37%). The number of mineralized bone-like nodules in cultures from BDL rats was 65% lower than that in cultures from sham-operated rats, attesting to a diminished number of osteoprogenitors.
CONCLUSIONS: Skeletal fragility diminished osteoprogenitor pool and elevated plasma levels of nitrite are three additional characteristics of the bone disease that develops in BDL rats, thus increasing the validity of this animal model as representing the human bone disease in patients with cholestatic liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123350     DOI: 10.1016/j.jhep.2003.11.032

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

2.  Hepatic osteodystrophy: An important matter for consideration in chronic liver disease.

Authors:  Germán López-Larramona; Alfredo J Lucendo; Sonia González-Castillo; José M Tenias
Journal:  World J Hepatol       Date:  2011-12-27

Review 3.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

4.  Rat model of cholelithiasis with human gallstones implanted in cholestasis-induced virtual gallbladder.

Authors:  Marlein Miranda Cona; Yewei Liu; Ting Yin; Yuanbo Feng; Feng Chen; Stefaan Mulier; Yue Li; Jian Zhang; Raymond Oyen; Yicheng Ni
Journal:  World J Methodol       Date:  2016-06-26

5.  Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction.

Authors:  Subhra Karmakar; Sangita Majumdar; Anasuya Maiti; Monalisa Choudhury; Aniruddha Ghosh; Asankur S Das; Chandan Mitra
Journal:  J Osteoporos       Date:  2011-06-23

Review 6.  Diagnosis and Management of Cirrhosis-Related Osteoporosis.

Authors:  Lívia Alves Amaral Santos; Fernando Gomes Romeiro
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

Review 7.  Organ-organ communication: The liver's perspective.

Authors:  Fei Wang; Kwok-Fai So; Jia Xiao; Hua Wang
Journal:  Theranostics       Date:  2021-01-16       Impact factor: 11.556

8.  Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti-γ-Glutamyl Transpeptidase Antibody.

Authors:  Yusuke Kawazoe; Mutsumi Miyauchi; Atsuhiro Nagasaki; Hisako Furusho; Syunryo Yanagisawa; Chea Chanbora; Toshihiro Inubushi; Hideyuki Hyogo; Takashi Nakamoto; Keiko Suzuki; Sawako Moriwaki; Susumu Tazuma; Shumpei Niida; Takashi Takata
Journal:  PLoS One       Date:  2015-09-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.